Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory illness in older adults. A major cause of COPD-related morbidity and mortality is acute exacerbation of COPD (AECOPD). Bacteria in the lungs play a role in exacerbation development, and the most common pathogen is non-typeable Haemophilus influenzae (NTHi). A vaccine to prevent AECOPD containing NTHi surface antigens was tested in a clinical trial. This study measured IgG and IgA against NTHi vaccine antigens in sputum. Sputum samples from 40 COPD patients vaccinated with the NTHi vaccine were collected at baseline and 30 days after the second dose. IgG and IgA antibodies against the target antigens and albumin were analyzed in the sputum. We compared antibody signals before and after vaccination, analyzed correlation with disease severity and between sputum and serum samples, and assessed transudation. Antigen-specific IgG were absent before vaccination and present with high titers after vaccination. Antigen-specific IgA before and after vaccination were low but significantly different for two antigens. IgG correlated between sputum and serum, and between sputum and disease severity. Sputum albumin was higher in patients with severe COPD than in those with moderate COPD, suggesting changes in transudation played a role. We demonstrated that immunization with the NTHi vaccine induces antigen-specific antibodies in sputum. The correlation between IgG from sputum and serum and the presence of albumin in the sputum of severe COPD patients suggested transudation of antibodies from the serum to the lungs, although local IgG production could not be excluded.Clinical Trial Registration: NCT02075541.
This work is motivated by randomized clinical trial NCT03281876 (November 2017–March 2020), whose secondary aim was to evaluate the efficacy of the NTHi-Mcat vaccine vs. placebo in preventing recurrent severe exacerbations among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The published analysis (Vaccine 40 (2022) 5924–5932; Lancet Respir. Med. 10 (2022) 435–446) aimed to estimate the ratio of the expected number of exacerbations one experienced by the end of study in the vaccinated vs. the placebo arm. One, therefore, regressed the number of exacerbations one experienced by the last point in time one is uncensored on treatment and baseline covariates with offset the logarithm of the observation time to account for different follow-up times. In this paper we demonstrate that this approach is prone to selection bias due to: (i) selective withdrawal and (ii) selective timing of the outcome measurements. We show that inverse probability of censoring weigting (IPCW), a common approach to adjust for dependent censoring under the assumption that censoring is noninformative given the observed covariate history, does not suffice to restore the unbiasedness of the treatment effect estimator under the above-mentioned type of analysis. To address this, we propose hazard inverse probability of censoring weighting (HIPCW). This novel weighting technique preserves the simplicity of IPCW but extracts more efficiency by using each individual’s last recorded outcome. We validate the proposed approach through extensive simulations and compare with: (i) IPCW at a single time, (ii) a variant of the existing IPCW-GEE routines (J. Amer. Statist. Assoc. 90 (1995) 106–121) and (iii) IPCW-based estimators derived from the popular Andersen-Gill model (J. R. Stat. Soc. Ser. B. Stat. Methodol. 66 (2004) 239–257). We illustrate the routines through reanalysing clinical trial NCT03281876.
This work is motivated by randomized clinical trial NCT03281876 (November 2017–March 2020), whose secondary aim was to evaluate the efficacy of the NTHi-Mcat vaccine vs. placebo in preventing recurrent severe exacerbations among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The published analysis (Vaccine 40 (2022) 5924–5932; Lancet Respir. Med. 10 (2022) 435–446) aimed to estimate the ratio of the expected number of exacerbations one experienced by the end of study in the vaccinated vs. the placebo arm. One, therefore, regressed the number of exacerbations one experienced by the last point in time one is uncensored on treatment and baseline covariates with offset the logarithm of the observation time to account for different follow-up times. In this paper we demonstrate that this approach is prone to selection bias due to: (i) selective withdrawal and (ii) selective timing of the outcome measurements. We show that inverse probability of censoring weigting (IPCW), a common approach to adjust for dependent censoring under the assumption that censoring is noninformative given the observed covariate history, does not suffice to restore the unbiasedness of the treatment effect estimator under the above-mentioned type of analysis. To address this, we propose hazard inverse probability of censoring weighting (HIPCW). This novel weighting technique preserves the simplicity of IPCW but extracts more efficiency by using each individual’s last recorded outcome. We validate the proposed approach through extensive simulations and compare with: (i) IPCW at a single time, (ii) a variant of the existing IPCW-GEE routines (J. Amer. Statist. Assoc. 90 (1995) 106–121) and (iii) IPCW-based estimators derived from the popular Andersen-Gill model (J. R. Stat. Soc. Ser. B. Stat. Methodol. 66 (2004) 239–257). We illustrate the routines through reanalysing clinical trial NCT03281876.
This work is motivated by randomized clinical trial NCT03281876 (November 2017–March 2020), whose secondary aim was to evaluate the efficacy of the NTHi-Mcat vaccine vs. placebo in preventing recurrent severe exacerbations among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The published analysis (Vaccine 40 (2022) 5924–5932; Lancet Respir. Med. 10 (2022) 435–446) aimed to estimate the ratio of the expected number of exacerbations one experienced by the end of study in the vaccinated vs. the placebo arm. One, therefore, regressed the number of exacerbations one experienced by the last point in time one is uncensored on treatment and baseline covariates with offset the logarithm of the observation time to account for different follow-up times. In this paper we demonstrate that this approach is prone to selection bias due to: (i) selective withdrawal and (ii) selective timing of the outcome measurements. We show that inverse probability of censoring weigting (IPCW), a common approach to adjust for dependent censoring under the assumption that censoring is noninformative given the observed covariate history, does not suffice to restore the unbiasedness of the treatment effect estimator under the above-mentioned type of analysis. To address this, we propose hazard inverse probability of censoring weighting (HIPCW). This novel weighting technique preserves the simplicity of IPCW but extracts more efficiency by using each individual’s last recorded outcome. We validate the proposed approach through extensive simulations and compare with: (i) IPCW at a single time, (ii) a variant of the existing IPCW-GEE routines (J. Amer. Statist. Assoc. 90 (1995) 106–121) and (iii) IPCW-based estimators derived from the popular Andersen-Gill model (J. R. Stat. Soc. Ser. B. Stat. Methodol. 66 (2004) 239–257). We illustrate the routines through reanalysing clinical trial NCT03281876.
9 June 2026 in Human Vaccines & Immunotherapeutics
Meningococcal vaccination of adolescents/young adults is recommended in various countries, including the United States (US). This phase 3b, observer-blind study (NCT04318548) evaluated the safety, reactogenicity, and immunogenicity of serogroup B vaccine, 4CMenB, and quadrivalent conjugate vaccine, MenACWY-CRM, when co-administered to healthy individuals aged 16–18 y, as per US Advisory Committee on Immunization Practices recommendations. Adolescents, who had received MenACWY vaccination ≥4 y previously, were randomized (N = 940; 1:1:1) to one of three groups to assess co-administration versus 4CMenB and MenACWY-CRM administered alone. Co-primary objectives were to demonstrate the non-inferiority of antibody responses after concomitant administration to antibody responses after 4CMenB (two doses administered 2 months apart) and MenACWY-CRM (single dose), as measured by human serum bactericidal assay (hSBA). Vaccine safety and reactogenicity were assessed as another primary objective. The co-primary endpoints were met: the lower limit of 2-sided 95% confidence intervals for all between-group ratios of hSBA geometric mean titers was >0.5 for the concomitant administration group versus 4CMenB group and MenACWY-CRM group. hSBA data after two 4CMenB doses and one MenACWY-CRM dose showed comparable between-group geometric mean ratios versus baseline, and percentages of participants with 4-fold rises in titers and titers ≥lower limit of quantitation. The safety profile of 4CMenB co-administered with MenACWY-CRM was comparable with that of 4CMenB administered alone. In conclusion, 4CMenB and MenACWY-CRM co-administration was well tolerated in adolescents aged 16–18 y and immune responses were comparable versus administration of each vaccine alone, which is consistent with a previous study of co-administration in infants.
This work is motivated by randomized clinical trial NCT03281876 (November 2017–March 2020), whose secondary aim was to evaluate the efficacy of the NTHi-Mcat vaccine vs. placebo in preventing recurrent severe exacerbations among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The published analysis (Vaccine 40 (2022) 5924–5932; Lancet Respir. Med. 10 (2022) 435–446) aimed to estimate the ratio of the expected number of exacerbations one experienced by the end of study in the vaccinated vs. the placebo arm. One, therefore, regressed the number of exacerbations one experienced by the last point in time one is uncensored on treatment and baseline covariates with offset the logarithm of the observation time to account for different follow-up times. In this paper we demonstrate that this approach is prone to selection bias due to: (i) selective withdrawal and (ii) selective timing of the outcome measurements. We show that inverse probability of censoring weigting (IPCW), a common approach to adjust for dependent censoring under the assumption that censoring is noninformative given the observed covariate history, does not suffice to restore the unbiasedness of the treatment effect estimator under the above-mentioned type of analysis. To address this, we propose hazard inverse probability of censoring weighting (HIPCW). This novel weighting technique preserves the simplicity of IPCW but extracts more efficiency by using each individual’s last recorded outcome. We validate the proposed approach through extensive simulations and compare with: (i) IPCW at a single time, (ii) a variant of the existing IPCW-GEE routines (J. Amer. Statist. Assoc. 90 (1995) 106–121) and (iii) IPCW-based estimators derived from the popular Andersen-Gill model (J. R. Stat. Soc. Ser. B. Stat. Methodol. 66 (2004) 239–257). We illustrate the routines through reanalysing clinical trial NCT03281876.